⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6403967 | 0.79 | — | — | |
| SCHEMBL10561097 | 0.77 | — | — | |
| SCHEMBL788277 | 0.72 | — | — | |
| SCHEMBL1533440 | 0.70 | — | — | |
| SCHEMBL3394983 | 0.70 | — | — | |
| SCHEMBL458328 | 0.70 | — | — | |
| SCHEMBL11636629 | 0.70 | — | — | |
| SCHEMBL9390790 | 0.70 | TSHR (0.33) | — | |
| SCHEMBL297052 | 0.69 | — | — | |
| SCHEMBL333601 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900301-B2 | Backbone modified oligonucleotide analogues | ISIS PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| US-20030045705-A1 | Backbone modified oligonucleotide analogues | ISIS PHARMACEUTICALS, INC. | 2003-03-06 | — | — | US | disclosed |
| US-20020183502-A1 | Backbone-modified oligonucleotide analogs and methods for using same | MESMAEKER ALAIN DE (CH) | 2002-12-05 | — | — | US | disclosed |
| EP-1004593-A2 | Backbone modified oligonucleotide analogues | ISIS PHARMACEUTICALS, INC. (US) | 2000-05-31 | — | — | EP | disclosed |
| US-5965721-A | WITH IMPROVED NUCLEASE RESISTANCE AND IMPROVED CELLULAR UPTAKE; FOR ANTISENSE AGENTS AND REGULATION OF RNA EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1999-10-12 | — | — | US | disclosed |
| US-5610289-A | Backbone modified oligonucleotide analogues | ISIS PHARMACEUTICALS, INC. (US) | 1997-03-11 | — | — | US | disclosed |
| US-5602240-A | MODULATE ACTIVITY OF DNA, RNA | CIBA GEIGY AG. (CH) | 1997-02-11 | — | — | US | disclosed |
| EP-0586570-A4 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGUES | ISIS PHARMACEUTICALS INC (US) | 1996-01-24 | — | — | EP | disclosed |
| EP-0586520-A4 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGS | ISIS PHARMACEUTICALS INC (US) | 1996-01-10 | — | — | EP | disclosed |
| US-5378825-A | Backbone modified oligonucleotide analogs | ISIS PHARMACEUTICALS, INC. (US) | 1995-01-03 | — | — | US | disclosed |
| EP-0586520-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 1994-03-16 | — | — | EP | disclosed |
| EP-0586570-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGUES | ISIS PHARMACEUTICALS, INC. (US) | 1994-03-16 | — | — | EP | disclosed |
| WO-1992020822-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGUES | ISIS PHARMACEUTICALS, INC. (US) | 1992-11-26 | — | — | WO | disclosed |
| WO-1992020823-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 1992-11-26 | — | — | WO | disclosed |